BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCRX shares.
View BCRX analyst ratings or view top-rated stocks.

7 analysts have issued 1 year price targets for BioCryst Pharmaceuticals' stock. Their BCRX share price targets range from $10.00 to $30.00. On average, they predict the company's share price to reach $13.29 in the next year. This suggests a possible upside of 190.1% from the stock's current price.
View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts.

BioCryst Pharmaceuticals' stock was trading at $5.99 at the start of the year. Since then, BCRX shares have decreased by 23.5% and is now trading at $4.58.
View the best growth stocks for 2024 here.

BioCryst Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 32,250,000 shares, an increase of 5.6% from the March 15th total of 30,550,000 shares. Based on an average daily volume of 3,290,000 shares, the days-to-cover ratio is currently 9.8 days.
View BioCryst Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our BCRX earnings forecast.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) released its earnings results on Monday, February, 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.04. The biotechnology company had revenue of $93.40 million for the quarter, compared to analyst estimates of $89.19 million.

ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Amplify Treatments, Testing and Advancements ETF (GERM) and Virtus LifeSci Biotech Products ETF (BBP).LeaderShares Activist Leaders ETF (ACTV).

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

BioCryst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Machelle Sanders, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends.

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.